Oramed Pharmaceuticals Inc. (ORMP) stock
ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.90+0.19 (+5.12%)
Close on Nov 16, 2026Market cap $162.23MP/E 1.1Yield 6.41%
Oramed Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Oramed Pharmaceuticals's price to sales ratio was 76.2× on Apr 30, 2026, against 50.1× a year earlier. Over the last 5 years it ranged from 19.6× to 305.7×, with a median of 59.8×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Apr 30, 2026 | 76.2× | +6.4 |
| 2024 | Apr 30, 2024 | 69.8× | +35.4 |
| 2023 | Dec 29, 2023 | 34.4× | −122.7 |
| 2022 | Dec 30, 2022 | 157.1× | −29.4 |
| 2021 | Dec 31, 2021 | 186.5× | +149.4 |
| 2020 | Dec 31, 2020 | 37.0× | +3.9 |
| 2019 | Dec 31, 2019 | 33.1× | +11.8 |
| 2018 | Dec 31, 2018 | 21.3× | −28.8 |
| 2017 | Dec 29, 2017 | 50.1× | −75.8 |
| 2016 | Dec 30, 2016 | 125.9× | – |
See a number that looks wrong?